ddC (Zalcitabine)

  • Gail Skowron
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

ddC (zalcitabine) is one of four nucleoside analogs currently approved by the Food and Drug Administration for the therapy of HIV infection. Despite its narrow therapeutic ratio, ddC has demonstrated in vivo activity against HIV disease, both alone and in combination with other drugs including AZT (zidovudine) and the protease inhibitor saquinavir.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Antimicrob Agent Human Immunodeficiency Virus Disease Triple Combination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Mitsuya, S. Broder. Inhibition of the in vitro infectivity and cytopathic effect of human T-Iymphotrophic virus type IIUlymphadenopathy-associated virus (HTLV III/LAV) by 2’,3’-dideoxynucleosides. Proc Natl Acad Sci. USA. 83: 1911–1915 (1986).CrossRefGoogle Scholar
  2. 2.
    W-Y. Gao, T. Shirasaka, D.G. Johns, et al. Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest. 91: 2326–2333 (1993).PubMedCrossRefGoogle Scholar
  3. 3.
    W-Y. Gao, R. Agbaria, J.S. Driscoll, et al. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2’,3’-dideoxynucleoside analogs in resting and activated human cells. J Biol Chem. 269: 12633–12638 (1994).PubMedGoogle Scholar
  4. 4.
    C-F. Perno, R. Yarchoan, D.A. Cooney, et al. Replication of human immunodeficiency virus in monocytes. Granulocyte/macrophage colony-stimulating factor (GMCSF) potentiates viral production yet enhances the antiviral effect mediated by 3’-azido-2’,3’-dideoxythymidine (AZT) and other dideoxynucleosides. J Exp Med. 169: 933–951 (1989).Google Scholar
  5. 5.
    J.J. Eron, V.A. Johnson, D.P. Merrill, et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2’,3’-dideoxycytidine in vitro. Antimicrob Agents Chemother. 36: 1559–1562 (1992).PubMedCrossRefGoogle Scholar
  6. 6.
    M.W. Vogt, A.G. Durno, T-C. Chou, et al. Synergistic interaction of 2’,3’-dideoxycytidine and recombinant interferon-a on replication of human immunodeficiency virus type 1. J Infect Dis. 158: 378–385 (1988).PubMedCrossRefGoogle Scholar
  7. 7.
    V.A. Johnson, D.P. Merrill, T-C. Chou, et al. Human immunodeficiency virus type 1 (HIV-I) inhibitory interactions between protease inhibitor Ro 31–8959 and zidovudine, 2’,3’-dideoxycytidine, or recombinant interferon-a against zidovudine-sensitive or -resistant HIV-1 in vitro. J Inf Dis. 166: 1143–1146 (1992).CrossRefGoogle Scholar
  8. 8.
    K-T. Chong, P.J. Pagano, R.R. Hinshaw. Bisheteroarylpiperazine reverse transcriptase inhibitor in combination with 3’-Azido-3’-Deoxythymidine or 2’,3’-Dddeoxycytidine synergistically inhibits human immunodeficiency virus type 1 replication in vitro. Antimicrob Agents Chemother. 38: 288–293 (1994).PubMedCrossRefGoogle Scholar
  9. 9.
    M.W. Vogt, K.L. Hartshorn, P.A. Furman, et al. Ribavirin antagonizes the effects of azidothymidine on HIV replication. Science. 235: 1376–1379 (1987).PubMedCrossRefGoogle Scholar
  10. 10.
    M. Baba, R. Pauwels, J. Balzarini, et al. Ribavirin antagonizes inhibitory effects of pyrimidine 2’, 3’dideoxynucleosides but enhances inhibitory effects of purine 2’,3’-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother. 31: 1613–1617 (1987).PubMedCrossRefGoogle Scholar
  11. 11.
    R.Yarchoan, C.R. Perno, R.V. Thomas, et al. Phase I studies of 2’, 3’ dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet. 1, 7681 (1988).Google Scholar
  12. 12.
    T.C. Merigan, G. Skowron, S. Bozzette, et al. Circulating p24 antigen levels and responses to dideoxycytidine in human immunodeficiency virus infections. Annals Int Med. 110: 189–94 (1989).CrossRefGoogle Scholar
  13. 13.
    A.R. Berger, J.C. Arezzo, H.H. Schaumburg, et al. 2’,3’-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology. 43: 358–362 (1993).PubMedCrossRefGoogle Scholar
  14. 14.
    T.C. Merigan, G. Skowron and the ddC Study Group of the AIDS Clinical Trials Group of the NIAID. Safety and tolerance of dideoxycytidine as a single agent. Amer J Med. 88 (suppl 5B): 11S - 15S (1990).PubMedCrossRefGoogle Scholar
  15. 15.
    M. Gottlieb, J. Galpin, J. Thompkins. 2’,3’-dideoxycytidine (ddC) in the treatment of patients with AIDS and ARC (abstract). Fifth International Conference on AIDS, Montreal, Canada, June 4–9, 1989.Google Scholar
  16. 16.
    R.W. Klecker, J.M. Collins, R.C. Yarchoan, et al. Pharmacokinetics of 2’,3’-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol. 28: 837–842 (1988).PubMedCrossRefGoogle Scholar
  17. 17.
    Hoffman La-Roche, letter to investigators, December 23, 1991.Google Scholar
  18. 18.
    M.A. Fischi, R.M. Olson, S.E. Follansbee, et al. Zalcitabine compared with zidovudine in patients with advanced HIV-1 infection who received previous zidovudine therapy. Ann Int Med. 118: 762–769 (1993).CrossRefGoogle Scholar
  19. 19.
    M. Fischi, K. Stanley, A. Collier, et al. Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med. 122: 24–32 (1995).CrossRefGoogle Scholar
  20. 20.
    Food and Drug Administration, Transcript of the Antiviral Drug Products Advisory Conunittee Meeting, September 20, 1993.Google Scholar
  21. 21.
    D.I. Abrams, A.I. Goldman, C. Lauver, et al. A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection. N Engl J Med. 330: 657–662 (1994).PubMedCrossRefGoogle Scholar
  22. 22.
    S.A. Spector, S. Blanchard, E.M. Conner, et al. Results of a clinical trial comparing two doses of 2’,3’-dideoxycytidine (ddC) in the treatment of children with symptomatic human immunodeficiency virus (HIV) infection who were intolerant or had failed zidovudine (ZDV) therapy (ACTG 138). Am Ped Soc. Abstract 1165: 197A (1994).Google Scholar
  23. 23.
    G. Skowron, SA Bozzette, L Lim, et al. Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Int Med 1993; 118: 321.PubMedCrossRefGoogle Scholar
  24. 24.
    S. Bozzette, G. Skowron, J. Arezzo,. ACTG 050: Alternating (ALT) and (INT) ddC and AZT in the treatment of persons with advanced HIV infection and hematologic intolerance to AZT. Sixth International Conference on AIDS, San Francisco, CA, June 20–24, 1990, abstract S.B.425.Google Scholar
  25. 25.
    P.A. Pizzo, K. Butler, F. Balis, et al. Dideoxycytidine alone and in an alternating schedule with zidovudine in children with symptomatic human immunodeficiency virus infection. J Ped. 117: 799–808 (1990).CrossRefGoogle Scholar
  26. 26.
    B-YT. Nguyen, L.E. Shay, K.M. Wyvill, et al. A pilot study of sequential therapy with zidovudine plus acyclovir, dideoxyinosine, and dideoxycytidine in patients with severe human immunodeficiency virus infection. J Infect Dis. 168: 810–817 (1993).PubMedCrossRefGoogle Scholar
  27. 27.
    M. Liu, J.L. Fahey, N. Aziz, et al. Zidovudine and dideoxycytidine differ in their effects on human immunodeficiency virus-induced pathologic activation of the immune system. J Infect Dis. 170: 1165–1171 (1994).PubMedCrossRefGoogle Scholar
  28. 28.
    D.D. Richman, J.M. Grimes, S.W. Lagakos. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immuno-deficiency virus. J AIDS. 3: 743–746 (1990).Google Scholar
  29. 29.
    D.D. Richman, M.A. Fischi, M.H. Grieco, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS-related complex: a double-blind, placebo-controlled trial. N Eng J Med. 317: 192–197 (1987).CrossRefGoogle Scholar
  30. 30.
    T-C. Meng, M.A. Fischi, A.M. Boota, et al. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection: a phase I/II study. Ann Int Med. 116: 13–20 (1992).PubMedCrossRefGoogle Scholar
  31. 31.
    D.D. Richman, T-C. Meng, S.A. Spector, et al. Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immunodeficiency virus. J AIDS. 7: 135–38 (1994).Google Scholar
  32. 32.
    R. Schooley, B. Larder, M. St. Clair,. Combination antiretroviral therapy in previously untreated individuals. Wellcome Foundation Symposium, Yokohama, Japan. August 7, 1994.Google Scholar
  33. 33.
    R. Bassett, D. Schoenfeld, A.C. Collier for the ACTG 229 Protocol Team. ACTG 229 Executive Summary. May 26, 1994. Division of AIDS, National Institute for Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.Google Scholar
  34. 34.
    A.C. Collier, R.W. Coombs, J. Timpone,. Comparative study of Ro31–8959 and Zidowdine (ZDV) vs. ZDV and Zalcitabine (ddC) vs. Ro 31–8959, ZDV, and ddC. 10th International Conference on AIDS, August 7–12, 1994, Yokohama, Japan, abstract 058B: 21.Google Scholar
  35. 35.
    T. Shirasaka, R. Yarchoan, M.C. O’Brien, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci. 90: 562–566 (1993).PubMedCrossRefGoogle Scholar
  36. 36.
    J.E. Fitzgibbon, R.M. Howell, C.A. Haberzettl, et al. Human immunodeficiency virus type 1 poi gene mutations which cause decreased susceptibility to 2’,3’-dideoxycytidine. Antimicrob Agents Chemother. 36: 153–157 (1992).PubMedCrossRefGoogle Scholar
  37. 37.
    J.E. Fitzgibbon, A.E. Farnham, S.J. Sperber, et al. Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol. 67: 7271–7275 (1993).PubMedGoogle Scholar
  38. 38.
    D.D. Richman, J.M. Grimes, and S.W. Lagakos. Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J AIDS. 3: 743–746. (1990).Google Scholar
  39. 39.
    R. Schuurman, M. Nijhuis, R. van Leeuwen, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 171: 1411–1419. (1995).PubMedCrossRefGoogle Scholar
  40. 40.
    Z. Gu, Q. Gao, X. Li, et al. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2’,3’-dideoxycytidine. J Virol. 66: 7128–7135 (1992).PubMedGoogle Scholar
  41. 41.
    D. Zhang, A.M. Caliendo, J.J. Eron, et al. Resistance to 2’,3’dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother. 38: 282–287 (1994).PubMedCrossRefGoogle Scholar
  42. 42.
    Z. Gu, Q. Gao, H. Fang, et al. Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2’,3’dideoxycytidine and 2’,3’dideoxy-3’-thiacytidine. Antimicrob Agents Chemother. 38: 275–281 (1994).PubMedCrossRefGoogle Scholar
  43. 43.
    B.A. Larder, S.D. Kemp, and P.R. Harrigan. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 269: 696–699. (1995).PubMedCrossRefGoogle Scholar
  44. 44.
    T. Shirasaka, M.F. Kavlick, T. Ueno, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci. USA. 92: 2398–2402. (1995).Google Scholar
  45. 45.
    M.H. St. Clair, J.L. Martin, G. Tudor-Williams, et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-lreverse transcriptase. Science. 253: 1557–1559 (1991).CrossRefGoogle Scholar
  46. 46.
    R.W. Shafer, M.J. Kozal, M.A. Winters, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type I strains with unique patterns of pol gene mutations. J Infect Dis. 169: 722–729. (1994).PubMedCrossRefGoogle Scholar
  47. 47.
    S.F. Lacey and B. A. Larder. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2’,3’-didehydro-2’,3’-dideoxythymidine in cell culture. Antimicrob Agents Chemother. 38: 1428–1432. (1994).PubMedCrossRefGoogle Scholar
  48. 48.
    D. Mayers, A. Japour, J-M. Arduino, et al. Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. Antimicrob Agents Chemother. 38: 307–314 (1994).PubMedCrossRefGoogle Scholar
  49. 49.
    MA. Sande, C.C.J. Carpenter, G. Cobbs, et al. Antiretroviral therapy for adult HIV-infected patients: Recommendations from a State-of-the-Art Conference. JAMA. 270: 2583–2589 (1993).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Gail Skowron

There are no affiliations available

Personalised recommendations